Dopavision, a Berlin, Germany-based company focused on development of digital therapeutics, raised €12M in Series A funding.
The round was led by Seventure Partners with participation from Novartis Pharmaceuticals, Boehringer Ingelheim Venture Fund and Ababax Health.
The company intends to use the funds for the clinical development of MyopiaX, its lead product in childhood myopia, activities to provide innovative digital treatments for children leveraging games, educational or cognitive training applications, and potentially broaden its pipeline to new indications, as well as for building the team.
Led by Hamed Bahmani, co-founder and managing director, Dopavision is advancing MyopiaX, which is designed to achieve a medical effect while children play games or use educational digital content and can be integrated into their daily routine.
The company has so far raised €14.7 million in private equity and public grants and is backed by top-tier international investors such as Seventure Partners, Novartis Pharma and Boehringer Ingelheim Venture Fund. Dopavision is supported by the German government via the “Industrie-in-Klinik” program of the German Federal Ministry of Education and Research BMBF (Aktionsfeld “Gesundheitswirtschaft im Rahmenprogramm Gesundheitsforschung”, Förderkennzeichen/contract number 13GW0256).
FinSMEs
16/07/2021